Targeted delivery systems of small interfering RNA by systemic administration.
about
Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.Therapeutic RNA manipulation in liver disease.A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitisAnti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.Enhanced delivery of PEAL nanoparticles with ultrasound targeted microbubble destruction mediated siRNA transfection in human MCF-7/S and MCF-7/ADR cells in vitro.PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.Ethical perspectives on RNA interference therapeutics.Ethanol treatment a Non-extrusion method for asymmetric liposome size optimization.Nonviral delivery of synthetic siRNAs in vivo.Gene therapy for osteosarcoma: steps towards clinical studies.Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cellsNonviral methods for siRNA deliveryUse of liposomes as drug delivery vehicles for treatment of melanoma.Targeted RNA interference for hepatic fibrosis.Strategies for targeted nonviral delivery of siRNAs in vivo.MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets.Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics.New short interfering RNA-based therapies for glomerulonephritis.RNA interference for performance enhancement and detection in doping control.Towards new therapeutic approaches for malignant melanoma.Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics.Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors.Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs.Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.Non-small cell lung carcinoma therapy using mTOR-siRNA.Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma.Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.Permanent acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system.In vivo siRNA delivery of Keap1 modulates death and survival signaling pathways and attenuates concanavalin-A-induced acute liver injury in mice.Light and electron microscopic detection of inflammation-targeting liposomes encapsulating high-density colloidal gold in arthritic mice.Grand challenges in modulating the immune response with RNAi nanomedicines.
P2860
Q34001975-DE4F4B3B-F9DE-4AD3-A1E1-16621AE434C2Q34244756-CF52795F-88C8-413D-8466-CED2F1821B6BQ34412219-06A8E644-34A3-421B-99F6-38ECDB28F797Q35563891-F12D5234-7F0D-4F45-BC9B-0031D13ECAADQ36015938-8C32A204-CF9A-4F54-A3A7-834F37A6DF46Q36161060-E8B454B8-DC69-414B-8D55-5B025F3342DEQ36743751-4352F684-91DC-4633-952F-AF6AEF889EE1Q36798580-27BD61E2-4251-4B67-B12D-C82F623CDE3FQ37024768-C93B1634-F42E-4714-A929-585FB0DBF72CQ37124981-AA21AA84-3DF4-41D5-BDA6-852089C73E47Q37157241-26646937-7A5E-4758-9896-AAE25E216F48Q37360226-DD9A842F-45D9-4BE1-B3C4-1B75D5D6A0A2Q37406217-012FC01C-67D7-49D8-A630-E3AF1D0967CEQ37590368-259B39AA-D6E5-41A7-9939-0B3FB7AE2990Q37619111-4C3B7EAC-B76D-45C5-91B6-3AD6D89AE9BFQ37724950-E2FADE46-064D-44FF-82A2-E05BC977A9CAQ37798545-80339359-6664-4182-969F-C85A139BC54DQ37879444-E6D00116-A796-482C-8273-42AC97E968D8Q37949928-AED4C010-AAB5-4963-866E-F5CDA2C717E0Q37951743-831DA394-1308-401C-A14C-E101632ED1CAQ37976494-0319C9CA-A58D-4DB9-B1EE-4577041D314BQ38002919-43005E80-C9C3-4326-9B8C-10C49E73D965Q38063945-272A7808-81A8-4AD6-8539-F4C1EFC5EB38Q38090525-235BE2D5-E124-4544-B535-18FF4E51826DQ38168518-1E58869B-6EF6-4271-9895-67D7BC1B8ECBQ38827570-9C522895-6EA2-46CC-A820-FF3458608F20Q39383412-44538889-9A92-4273-9246-F75E7C2BCBD6Q39563581-3BB9B54E-457B-4C9F-A2EC-40149FA7C683Q39831915-F0B8D644-5866-44F5-8F1C-C07F92416808Q41557539-5BB92BC4-E2A1-4899-B288-0B7C8AC02579Q42837335-4D058E79-FF22-471B-88CD-A298B1E7C7D3Q43664324-3DD08CF0-087A-4011-AEA1-9FA272E5EC36Q47578379-6B0868CD-1010-471F-96A7-A41B9BE14ACE
P2860
Targeted delivery systems of small interfering RNA by systemic administration.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeted delivery systems of small interfering RNA by systemic administration.
@en
type
label
Targeted delivery systems of small interfering RNA by systemic administration.
@en
prefLabel
Targeted delivery systems of small interfering RNA by systemic administration.
@en
P356
P1476
Targeted delivery systems of small interfering RNA by systemic administration.
@en
P2093
Mitsuru Hashida
Shigeru Kawakami
P304
P356
10.2133/DMPK.22.142
P577
2007-06-01T00:00:00Z